Back to all blogs
We're excited to share a groundbreaking discussion from our Behavioral Health Innovators series, presented by Lightning Step Technologies, live from the NAATP Conference 2024! Host Benjamin Turner sat down with Ellen Frenkel, Chief Commercial Officer at Spark Biomedical Inc., to explore their innovative approach to opioid use disorder treatment.
Ellen introduced Spark's non-invasive neurostimulation device, which targets the brain's endogenous opioid network. Key highlights:
⚡ Complements existing treatment protocols, working with or without medication-assisted treatment
⚡ Patients can control their stimulation, with significant symptom reduction in 30-60 minutes
⚡ Flexible use in inpatient, outpatient, or home settings with a prescription
⚡ Founded by neuroscientists, with ongoing clinical research to expand indications
Most excitingly, Spark is committed to expanding therapeutic options for those struggling with addiction, offering a science-based alternative or complement to traditional approaches.
Tune in to learn how cutting-edge medical technology transforms addiction treatment and offers new hope to those in recovery!
